A PhD training position on cancer immunotherapy and chemical tumor cell targeting is immediately available in the laboratory of Peter Friedl, MD, PhD, in the Department of Cell Biology, Radboud Institute of Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
ICI member Prof. Huib Ovaa has been awarded the Bessel award or the “Friedrich Wilhelm Bessel-Forschungspreis” from the Alexander von Humboldt Foundation.
This award has been granted in recognition of past accomplishments in research and teaching.
Executive Board member Prof. Carl Figdor has been awarded an ERC Advanced Grant of € 2.5 million.
Chemist Mario van der Stelt was appointed Professor of Molecular Physiology at the Leiden Institute of Chemistry with effect from 1 November 2017. On Friday October 19th 2018 he gave his inaugural lecture entitled Body's own marijuana: inspiration for drug research.
The full lecture (in Dutch) can be found here.
Prof. Hidde Ploegh has been appointed professor Chemical Immunology, in particular biochemistry of the immune system, at the LUMC. He will take on the Jon J. van Rood Chair effective as of September 1st.
Improved method for quality control of biopharmaceuticals
ICI Executive Board member Albert Heck (Utrecht University) is to receive two international distinctions this summer for his work in biochemistry and mass spectrometry: the prestigious Sir Hans Krebs Medal and the Thomson Medal and Prize. 'It is a wonderful and special honour, especially since they are two completely different awards.'
On September 17th, the Royal Netherlands Academy of Arts and Sciences (KNAW) will install 21 new members, including ICI executive board member Hermen Overkleeft (Leiden University). Since its inception, the Academy has been a learned society of outstanding Dutch scientists and scholars. Membership is awarded on the basis of scientific and scholarly achievement. Members are appointed for life
What determines cell fate?
Vaccination is a powerful strategy to induce the activation of tumor‐specific effector immune cells, which is key for successful immunotherapy. However, the generation of effective anticancer nanovaccines is challenging. One of these challenges is the efficient co-encapsulation of antigenic peptides or proteins together with antigen-presenting cell activating adjuvants because of their differential physicochemical properties.